Yahoo
NasdaqCM - Nasdaq Real Time Price USD

60 Degrees Pharmaceuticals, Inc. (SXTP)

0.9495 -0.0705 (-6.91%)
At close: September 2 at 4:00:00 PM EDT
0.9800 +0.0305 (+3.21%)
Pre-Market: 8:39:15 AM EDT
Chart Range Bar
Loading chart for SXTP
  • Previous Close 1.0200
  • Open 1.0300
  • Bid 0.7560 x 200
  • Ask 1.2100 x 200
  • Day's Range 0.9000 - 1.0500
  • 52 Week Range 0.9000 - 8.6200
  • Volume 86,423
  • Avg. Volume 106,180
  • Market Cap (intraday) 3.339M
  • Beta (5Y Monthly) 2.54
  • PE Ratio (TTM) --
  • EPS (TTM) -2.6700
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 3.70

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Washington, District Of Columbia.

www.60degreespharma.com

3

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SXTP
53.27%
S&P 500 (^GSPC)
11.99%

1-Year Return

SXTP
83.28%
S&P 500 (^GSPC)
19.50%

3-Year Return

SXTP
99.72%
S&P 500 (^GSPC)
69.77%

5-Year Return

SXTP
99.89%
S&P 500 (^GSPC)
68.98%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 162.09k
Earnings -2.09M
Profit Margin -1,288.91%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-2M
-2M
-1M
-500K
0
-1600.0%
-1400.0%
-1200.0%
-1000.0%
-800.0%
-600.0%

Analyst Insights

View More

Analyst Price Targets

3.70
3.70 Average
0.9495 Current
3.70 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/22/2026
Analyst Ascendiant Capital
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 4.2 -> 3.7

Statistics

View More

Valuation Measures

Annual
As of 9/1/2026
  • Market Cap

    3.60M

  • Enterprise Value

    12.30M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.47

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    11.07

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -127.11%

  • Return on Equity (ttm)

    -332.85%

  • Revenue (ttm)

    1.21M

  • Net Income Avi to Common (ttm)

    -8.62M

  • Diluted EPS (ttm)

    -2.6700

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.02M

  • Total Debt/Equity (mrq)

    5.98%

  • Levered Free Cash Flow (ttm)

    -6.08M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

0.9495 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: